1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


TABLE 1: 
Descriptive statistics of different tumor groups
Tumor Type*n (%)ParameterMean/SD/SE95% CI for MeanRange
LGGT (I–II/IV)36/75 (48.00)rCBVT2.30/1.12/0.191.92–2.680.84–5.73
rCBVP1.18/0.24/0.041.10–1.260.77–1.86
LGAT (I–II/IV)24/75 (32.00)rCBVT1.75/0.38/0.081.59–1.910.84–2.52
rCBVP1.15/0.23/0.051.05–1.250.77–1.86
LGODG (II/IV)12/75 (16.00)rCBVT3.40/1.29/0.372.59–4.221.73–5.73
rCBVP1.23/0.25/0.071.07–1.380.87–1.83
HGGT (III–IV/IV)22/75 (29.33)rCBVT5.42/1.52/0.334.74–6.093.15–8.96
rCBVP2.17/0.82/0.181.80–2.531.00–4.14
HGAT (III–IV/IV)15/75 (20.00)rCBVT4.78/0.99/0.264.23–5.333.15–6.58
rCBVP1.99/0.59/0.151.66–2.311.00–3.09
HGODG (III/IV)7/75 (9.33)rCBVT6.78/1.63/0.625.27–8.294.55–8.96
rCBVP2.55/1.15/0.431.49–3.611.23–4.14
MET17/75 (22.67)rCBVT3.21/0.98/0.242.70–3.711.27–5.60
rCBVP0.97/0.09/0.020.93–1.020.80–1.13
  • Note.—LGGT indicates low-grade glial tumor; LGAT, low-grade astrocytic tumor; LGODG, low-grade oligodendroglioma; HGGT, high-grade glial tumor; HGAT, high-grade astrocytic tumor; HGODG, high-grade oligodendroglioma; MET, metastasis; rCBVT, tumoral relative cerebral blood volume; rCBVP, peritumoral relative cerebral blood volume.
  • * Roman numerals in parentheses show tumor grade according to the World Health Organization 2000 classification scheme.